Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

800.29 -2.88 (-0.36%)
Streaming Delayed Price Updated: 10:45 AM EDT, May 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
79 80 Next >
SPDR ETF Report For Friday, March 22
In this video, Ira Epstein reviews the day's trading in various SPDR-ETF markets for the trading day just ended, Friday, March 22. 
Via Talk Markets
Topics ETFs
Hot Stocks: The 3 Best Opportunities for Investing in Weight Loss Drugs
The market for weight loss drug stocks is massive, and these three companies could be the biggest beneficiaries of this trend. 
Via InvestorPlace
Don’t Sleep On Global Stocks
ESTX50 and DAX have kept up with SPX over the past three years and six months, even if NDX outpaces them nonetheless. 
Via Talk Markets
Comparative Study: Eli Lilly and Co And Industry Competitors In Pharmaceuticals Industry
Via Benzinga
Ozempic Users Speak Out Over Side Effects, Lawsuits Against Novo Nordisk And Eli Lilly Surge
Legal actions surge against diabetes drug manufacturers Eli Lilly and Novo Nordisk. Patients allege severe complications, including gallbladder issues and gastroparesis, tied to GLP-1 agonists. Over 60... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Eli Lilly and Co's Options Frenzy: What You Need to Know
Via Benzinga
With Shares Trading Near All-Time Highs, Is Now the Time to Take Profits in Novo Nordisk?
The success of Ozempic and Wegovy has fueled Novo Nordisk stock to new highs. 
Via The Motley Fool
Did Eli Lilly Just One-Up Novo Nordisk?
Eli Lilly just partnered with Amazon to help accelerate distribution of its various treatments. 
Via The Motley Fool
Could Viking Therapeutics Become the Next Eli Lilly?
Viking shares have skyrocketed on its recent good news. 
Via The Motley Fool
Medicare Will Cover Weight-Loss Drugs — For Some. Here's What It Means For Novo, Lilly.
Novo Nordisk's Wegovy recently gained Food and Drug Administration approval to reduce the risk of cardiovascular problems. 
Via Investor's Business Daily
Wegovy's Success - Medicare Contemplates Covering Novo Nordisk's Semaglutide For Heart Health
Medicare considers extending coverage for Novo Nordisk's Wegovy to eligible members with heart disease history. CMS may include anti-obesity drugs under certain Medicare Part D plans. Germany's health... 
Via Benzinga
Amazon’s 1-2 Punch: AI-Powered Listings and Eli Lilly Deal Make AMZN a Must-Buy
AMZN stock can easily continue to run higher as Amazon rolls out more AI features and works closely with a famous pharmaceutical giant. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Is Eli Lilly Winning The War On Weight Loss Drugs? Zepbound Overtakes Wegovy In US Prescriptions
Eli Lilly stock is up 32% so far in 2024 and has risen 318% over three years. 
Via Benzinga
Healthcare And Biotech Update With Market At 2024 Highs
The bull market is intact with technology Stocks dominating, but XLV is up 6.89%YTD. 
Via Talk Markets
Wall Street’s Favorite Tech Stocks? 3 Names That Could Make You Filthy Rich
Bet on success with Wall Street's favorite tech stocks. These investments have the potential to outperform the market. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Will Novo Nordisk Overtake Eli Lilly as the Most Valuable Healthcare Stock?
The gap has been shrinking between these stocks over the past month. 
Via The Motley Fool
3 Stocks Ready to Ride the Bull Higher
Each of these securities is rising on strong earnings prints and catalysts that could send their share prices upwards in coming months. 
Via InvestorPlace
3 Juicy Stocks Serving Up 5% Dividends That You Can Snag for $50
These dividend stocks selling for under $50 with yields of 5% or more offer a lot to investors at any time making these strong buys. 
Via InvestorPlace
Visualizing The Biggest Companies On Major Stock Exchanges
The NYSE’s largest companies are more diversified, with a combination of tech, financial services, and healthcare names present. 
Via Talk Markets
What Retail Apocalypse? 7 Stocks Proving the Doomsayers Wrong.
People have said retail is dying for years now but the supposed apocalypse is nowhere to be found with these fast-charging retail stocks. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Cramer Calls Datadog 'Dynamite,' Puts SoFi In Dog House: 'What The Heck Is Going On'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Marvell Technology, Inc. (NASDAQ: MRVL) reported a mixed quarter. 
Via Benzinga
Fusion Pharma Stock Nearly Doubles After Scoring $2 Billion AstraZeneca Takeover
The company is working on radiopharmaceuticals treatments for cancer. 
Via Investor's Business Daily
Did Novo Nordisk Just Get a Jump on Eli Lilly?
A recent FDA announcement may have just put one company in the lead. 
Via The Motley Fool
Exposures Product Safety
AstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer Treatments
AstraZeneca to acquire Fusion Pharmaceuticals for $21.00 per share cash plus $3.00 per share CVR upon regulatory milestone achievement, marking a significant $2.4 billion deal. Enhancing cancer... 
Via Benzinga
Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?
Madrigal has one key advantage over its two huge potential future rivals. 
Via The Motley Fool
Exposures Product Safety
Wall Street’s Favorite Growth Stocks? 7 Names That Could Make You Filthy Rich
Growth stocks should continue to rise as the S&P 500 hits new highs, with rate cuts on the horizon expected to continue fueling the rally. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
US Prescriptions Race For Weight Loss Drugs - Eli Lilly's Zepbound Overtakes Novo Nordisk's Wegovy
Latest in weight-loss medication trends: Eli Lilly And Co's Zepbound (tirzepatide) surges past rival Novo Nordisk A/S's Wegovy (semaglutide) in new prescriptions, signaling a shift in the obesity... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
79 80 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.